Last reviewed · How we verify
Oxfendazole single dose
At a glance
| Generic name | Oxfendazole single dose |
|---|---|
| Also known as | Intervention 1 |
| Sponsor | Universidad Peruana Cayetano Heredia |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Safety and Efficacy Study of Different Doses of Oxfendazole Compared to a Single Dose of Albendazole to Treat Trichuris Trichiura Infection in Adults (PHASE2)
- One and Two Doses of Oxfendazole Versus a Schedule of Two Doses of Triclabendazole in Chronic Fascioliasis (PHASE2)
- Oxfendazole in Mild Parenchymal Brain Cysticercosis (PHASE2, PHASE3)
- Efficacy of Oxfendazole in the Treatment of Trichuris Trichiura Infection in Adults (PHASE2)
- PK, Safety and Tolerability of Single and Multiple Doses of Oxfendazole Tablets (PHASE1)
- Phase I Trial Evaluating the Safety and Pharmacokinetics of Oxfendazole (PHASE1)
- Study of the Efficacy of Oxfendazole Compared to Albendazole in the Treatment of Trichuris Trichiura Infection in Adults (PHASE2)
- Single Ascending Dose Safety Study of Oxfendazole (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oxfendazole single dose CI brief — competitive landscape report
- Oxfendazole single dose updates RSS · CI watch RSS
- Universidad Peruana Cayetano Heredia portfolio CI